LPA and cancer: BrP-LPA, a pan-LPAR antagonist, was used to treat breast MDA-MB-231 cancer cells, and Zhang et al. found more decreased intra-tumoral blood vessel density treated by BrP-LPA (10 mg/kg) compared with those by paclitaxel (10 mg/kg) [112].